|
|
|
|
| LEADER |
00000cam a2200000 4500 |
| 001 |
EBSCO_ocn957126295 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr |n|---||||| |
| 008 |
160820s2016 xx o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d YDX
|d EBLCP
|d OCLCQ
|d OCLCF
|d N$T
|d AGLDB
|d D6H
|d OCLCQ
|d VTS
|d STF
|d OCLCQ
|d UKSSU
|d OCLCO
|d OCLCQ
|
| 019 |
|
|
|a 956747086
|a 959534990
|a 959649506
|a 1010973709
|a 1087408883
|a 1162192367
|a 1264948669
|
| 020 |
|
|
|a 9781681082318
|q (electronic bk.)
|
| 020 |
|
|
|a 1681082314
|q (electronic bk.)
|
| 029 |
1 |
|
|a AU@
|b 000070393173
|
| 029 |
1 |
|
|a DEBSZ
|b 493176616
|
| 035 |
|
|
|a (OCoLC)957126295
|z (OCoLC)956747086
|z (OCoLC)959534990
|z (OCoLC)959649506
|z (OCoLC)1010973709
|z (OCoLC)1087408883
|z (OCoLC)1162192367
|z (OCoLC)1264948669
|
| 050 |
|
4 |
|a RC523
|b .F76 2016
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.8/31
|2 23
|
| 049 |
|
|
|a UAMI
|
| 100 |
1 |
|
|a Atta-ur-Rahman.
|
| 245 |
1 |
0 |
|a Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5.
|
| 260 |
|
|
|a Sharjah :
|b Bentham Science Publishers,
|c 2016.
|
| 300 |
|
|
|a 1 online resource (328 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a PREFACE ; List of Contributors ; Should Physicians Screen for Dementia in the Primary Care Setting? ; INTRODUCTION; SECTION 1: SHOULD WE SCREEN FOR DEMENTIA?; Considerations in Screening for a Disease; Does Dementia Pass Muster as a Disease Worthy of Screening? ; CRITERION 1: How Prevalent and Costly is Alzheimer's disease?; CRITERION 2: Are Early Stages of Dementia not Obvious?; CRITERION 3: Are Screening Tools Cheap and Effective?; CRITERION 4: Does the Potential Harm from a False Positive or False Negative Test Outweigh the Positive Benefit from Screening?
|
| 505 |
8 |
|
|a Criterion 5: Does Earlier Diagnosis of Dementia or Cognitive Impairment Make a Difference?Potential Non-Disease Indirect Benefits of Screening for Dementia; Potential Benefit of Early Detection #1: Alerting Physician to Potential Medication Compliance Problems; Potential Benefit of Early Detection #2: Alerting Physicians to the Risk of Post-Operative Delirium; Potential Benefit of Early Detection #3: Additional Time for Family Planning; Potential Benefit of Early Detection #4: Assessing Patient's Competence at Work and Managing Finances.
|
| 505 |
8 |
|
|a Potential Benefit of Early Detection #5: Identifying Unsafe Drivers Before it is too latePotential Benefit #6-Identification of Potentially Reversible Dementias-and Reversing Them; Potential Benefit #7: Identification of Patients for Research Program Participation; Potential Benefit #8: Establishment of a Cognitive Baseline; The Key Question: Can Earlier Intervention in Dementia Make a Difference?; SECTION 2: BEDSIDE TESTS FOR DEMENTIA SCREENING ; The Mini-Mental State [44]; Montreal Cognitive Assement (MoCA) [47]; The Clock Draw Test; The Mini-Cog [58].
|
| 505 |
8 |
|
|a Buschke's Memory Impairment Screen [61]Semantic and Lexical Fluency Tasks as Screening Tools; The Hopkins Verbal Learning Test (HVLT) [71]; The Q & E (Quick and Easy); CONCLUSION; NOTES; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Endothelial Dysfunction and Chronic Low-Grade Inflammation as Potential Therapeutic Targets in Dementia Disorders ; INTRODUCTION; Endothelial Dysfunction and Chronic Low-Grade Inflammation as a Possible Link between Cardiometabolic Disorders and Dementia; Endothelial Dysfunction and Dementia.
|
| 505 |
8 |
|
|a Treatment Options Targeting Endothelial Dysfunction and Chronic Low-Grade Inflammation in Dementia DisordersEndothelin Receptor Antagonists; Anti-Inflammatory Drugs; Nonsteroidal Anti-Inflammatory Drugs ; Cytokine Suppressive Anti-Inflammatory Drugs; CONCLUSION; ACKNOWLEDGEMENTS; CONFLICT OF INTEREST; REFERENCES; Recent Clinical Developments in Alzheimer's Disease ; INTRODUCTION; Therapeutic Strategies and Clinical Trials; Cholinergic Hypothesis; Amyloid Cascade Hypothesis; Inflammation in AD ; Metal Dyshomeostasis in AD; Future Development: Challenges and Recent Advances.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Alzheimer's disease.
|
| 650 |
|
2 |
|a Alzheimer Disease
|
| 650 |
|
6 |
|a Maladie d'Alzheimer.
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Alzheimer's disease.
|2 fast
|0 (OCoLC)fst00806532
|
| 776 |
0 |
8 |
|i Print version:
|a Atta-ur-Rahman.
|t Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5.
|d Sharjah : Bentham Science Publishers, ©2016
|z 9781681082325
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1511895
|z Texto completo
|
| 936 |
|
|
|a BATCHLOAD
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL4625092
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 1511895
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 13115636
|
| 994 |
|
|
|a 92
|b IZTAP
|
